ATE251912T1 - Verwendung des erythropoietins zur behandlung von rheumatoider arthritis - Google Patents

Verwendung des erythropoietins zur behandlung von rheumatoider arthritis

Info

Publication number
ATE251912T1
ATE251912T1 AT95936127T AT95936127T ATE251912T1 AT E251912 T1 ATE251912 T1 AT E251912T1 AT 95936127 T AT95936127 T AT 95936127T AT 95936127 T AT95936127 T AT 95936127T AT E251912 T1 ATE251912 T1 AT E251912T1
Authority
AT
Austria
Prior art keywords
treatment
rheumatoid arthritis
erythropoietin
epo
seen
Prior art date
Application number
AT95936127T
Other languages
English (en)
Inventor
Anthonius Josef Gerardus Swaak
Original Assignee
Roche Diagnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Diagnostics Gmbh filed Critical Roche Diagnostics Gmbh
Application granted granted Critical
Publication of ATE251912T1 publication Critical patent/ATE251912T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT95936127T 1994-11-03 1995-10-26 Verwendung des erythropoietins zur behandlung von rheumatoider arthritis ATE251912T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94203205 1994-11-03
PCT/NL1995/000370 WO1996014081A1 (en) 1994-11-03 1995-10-26 Use of erythropoietin in the treatment of rheumatoid arthritis

Publications (1)

Publication Number Publication Date
ATE251912T1 true ATE251912T1 (de) 2003-11-15

Family

ID=8217342

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95936127T ATE251912T1 (de) 1994-11-03 1995-10-26 Verwendung des erythropoietins zur behandlung von rheumatoider arthritis

Country Status (9)

Country Link
US (2) US7344717B1 (de)
EP (1) EP0784480B1 (de)
AT (1) ATE251912T1 (de)
AU (1) AU3817495A (de)
DE (1) DE69531952T2 (de)
ES (1) ES2206521T3 (de)
IL (1) IL115826A (de)
WO (1) WO1996014081A1 (de)
ZA (1) ZA959325B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5952226A (en) * 1996-11-05 1999-09-14 Modex Therapeutiques Hypoxia responsive EPO producing cells
DE19734293A1 (de) 1997-08-08 1999-02-11 Boehringer Mannheim Gmbh Verwendung von pharmazeutischen Kombinationspräparaten enthaltend Erythropoietin und Eisenpräparate zur Behandlung von rheumatischen Erkrankungen
WO2001082952A2 (en) * 2000-05-02 2001-11-08 Action Pharma Aps USE OF α-MSH AND EPO FOR PREVENTING OR TREATING ISCHEMIC CONDITIONS
DE10234192B4 (de) 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
US9610444B2 (en) 2013-03-15 2017-04-04 Pacesetter, Inc. Erythropoeitin production by electrical stimulation
IL308638A (en) * 2021-05-18 2024-01-01 Attias Eyal Use of erythropoietin or a substance that encourages erythropoiesis, to treat osteomyelitis and bone infection

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4732889A (en) 1985-02-06 1988-03-22 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for the treatment of the anemia of rheumatoid arthritis
US5013718A (en) * 1986-11-21 1991-05-07 Amgen, Inc. Method for treating iron overload using EPO

Also Published As

Publication number Publication date
IL115826A (en) 2000-07-26
AU3817495A (en) 1996-05-31
WO1996014081A1 (en) 1996-05-17
US7344717B1 (en) 2008-03-18
DE69531952T2 (de) 2004-07-29
ES2206521T3 (es) 2004-05-16
US20070249525A1 (en) 2007-10-25
EP0784480B1 (de) 2003-10-15
ZA959325B (en) 1996-05-29
EP0784480A1 (de) 1997-07-23
DE69531952D1 (de) 2003-11-20
IL115826A0 (en) 1996-01-19
US9155782B2 (en) 2015-10-13

Similar Documents

Publication Publication Date Title
NO972451L (no) Heterosyklyloksy- og tiometyl-1,2,5-tiadiazolidin-3-on 1,1-dioksyder og preparater og fremgangsmåte for anvendelse derav
DK0429570T3 (da) Osteoinducerende præparater
AU1049788A (en) Methods and peptides for the treatment of non-ige-mediated diseases
ATE218350T1 (de) Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen
NO972391D0 (no) 2-substituerte 1,2,5-tiadiazolidin-3-on 1,1-dioksider og preparater og metoder for anvendelse derav
AU2742892A (en) An anticoagulant substance obtained from urine
DE69631656D1 (de) Debromhymenialdisin und verwandte verbindungen zur behandlung von osteoarthritis
ATE251912T1 (de) Verwendung des erythropoietins zur behandlung von rheumatoider arthritis
DE69805305D1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
DE68921229D1 (de) Prozess zur Behandlung von unlöslichem heterogenem Fusionsprotein.
NO972449L (no) Substituerte 2-arylkarbonyloksymetyl-1,2,5-tiadiazolidin-3-on-1,1-dioksidderivater og preparater og fremgangsmåte for anvendelse derav
DE69433243D1 (de) Verwendunf von ApoE zum Binden von TAU und MAP2c Proteinen und zur Behandlung von Alzheimer's Krankheit
DE69619051D1 (de) Behandlung von Füllstoffen mit Oxasilacycloalkanen
ATE151774T1 (de) Cyclopentanperhydrophenanthren-17-beta-(3-furyl - 3-derivate und pharmazeutische präparate davon, zur behandlung von kardiovaskulär-erkrankungen
DE69621786T2 (de) Aminotetralinderivat zur behandlung von herzkreislauferkrankung
DE59708511D1 (de) Verwendung von 7-(1-aminomethyl-2-oxa-7-aza-bicyclo 3.3.0]oct-7-yl)-chinoloncarbonsäure- und -naphthyridoncarbonsäure-derivaten zur therapie von helicobacter-pylori-infektionen und den damit assoziierten gastroduodenalen erkrankungen
DE69734890D1 (de) Rdgb-proteine
DE69113773D1 (de) Verwendung von 3-aryl-5-alkylthio-4H-1,2,4-triazolen zur Behandlung von Überreflexen infolge von Rückenmarkstrauma.
MX9704035A (es) 1,1-dioxidos de 2-(fosfiniloximetil)-1,2,5-tiadiazolidin-3-ona substituidos y composiciones y metodo de uso de los mismos.
DE69609541T2 (de) Verwendung von 6,7-substituierten-2-Aminotetraline zur Herstellung von pharmazeutischen Zusammensetzungen zur Behandlung von septischem Schock, und antipyretischer und antientzündlicher Zusammensetzungen
DE59410340D1 (de) Verwendung von Bradykinin-Antagonisten zur Behandlung von Viruserkrankungen
MX9704036A (es) 1,1-dioxidos y composiciones de 2-(2,3,5,6-tetrafluoro-4-piridil)-1,2,5-thiadizaolidin-3-ona y metodo de uso.
DE69313534T2 (de) Digitoxigenin und Dihydrodigitoxigenin 3-beta-Derivate und pharmazeutische Präparate davon, zur Behandlung von hypertonie
ITRM940751A0 (it) Metodo per la realizzazione semi-industriale di calzature ortopediche personalizzate e forme componibili per l'attuazione dello stesso.
IT9048106A0 (it) Associazione medicamentosa per il trattamento dell'ipertensione e dell'insufficienza cardiaca congestiva. (caso 100-7516)

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0784480

Country of ref document: EP